PubRank
Search
About
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation (Occlusion-AF)
Clinical Trial ID NCT03642509
PubWeight™ 0.00
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT03642509
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med
2009
39.97
2
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med
2011
28.99
3
Apixaban versus warfarin in patients with atrial fibrillation.
N Engl J Med
2011
23.50
4
Edoxaban versus warfarin in patients with atrial fibrillation.
N Engl J Med
2013
7.70
5
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation.
Ann Thorac Surg
1996
4.72
6
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
JAMA
2014
4.13
7
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Lancet Neurol
2010
3.26
8
Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.
Stroke
2005
3.07
9
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
J Am Coll Cardiol
2014
3.01
10
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Lancet Neurol
2012
2.77
11
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J
2016
2.70
12
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Lancet Neurol
2012
1.99
13
Epidemiology of atrial fibrillation: European perspective.
Clin Epidemiol
2014
1.39
14
Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.
EuroIntervention
2016
1.11
15
Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.
Eur Heart J
2016
1.05
16
Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Basic Clin Pharmacol Toxicol
2016
0.78
17
Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.
Eur Heart J
2017
0.78
18
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke
2016
0.75
19
Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study.
EuroIntervention
2017
0.75
20
Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials.
Heart
2016
0.75
21
Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies.
EuroIntervention
2016
0.75
Next 100